$8.3 Million Awarded For 2019-nCoV Vaccine Development

CureVac and CEPI partner to develop a rapid-response coronavirus vaccine development platform

putting together puzze pieces for the vaccine dev

A Germany / USA based biopharmaceutical company announced a collaboration with the Coalition for Epidemic Preparedness Innovations (CEPI) to develop a vaccine against the new coronavirus 2019-nCoV.

The 2019-nCoV outbreak began during December 2019 in Wuhan, China, and has spread to various countries around the globe.

The aim of the cooperation agreement announced by CureVac AG on January 31, 2020, is to safely advance vaccine candidates into clinical testing as quickly as possible. 

The agreement will build on the existing partnership between CureVac and CEPI to develop a rapid-response vaccine platform and includes additional initial funding of up to $8.3 million from CEPI.

“CureVac’s technology and messenger RNA (mRNA) platform are especially suitable to rapidly provide a response to a viral outbreak situation like this,” said Dr. Mariola Fotin-Mleczek, Chief Technology Officer of CureVac AG, in a press release.

“Currently, we are in the process of developing a vaccine that, after successful preclinical tests, could be tested rapidly in humans in a clinical study.”

In addition, CureVac is working on the development of The RNA Printer™, which is a mobile, automated production unit for rapid mRNA supply. 

In February 2019, CEPI agreed to provide up to $34 million in support of CureVac’s technology development, which will provide a rapid supply of lipid-nanoparticle-formulated mRNA vaccine candidates that can target known pathogens and prepare for rapid response to new and previously unknown pathogens.

Additionally, the Federal Ministry of Education and Research has committed a total of 90 million euros to support this work.

As an example of this project, CureVax announced on January 7, 2020, positive data from its Phase 1 clinical trial evaluating CV7202, a novel prophylactic mRNA-based rabies vaccine.

CureVac AG is a leading clinical-stage biotechnology company in the field of messenger RNA (mRNA) technology with 20 years of expertise in developing and optimizing this versatile molecule for medical purposes. The principle of CureVac's proprietary technology is the use of mRNA as a data carrier to instruct the human body to produce its own proteins capable of fighting a wide range of diseases. 

Novel coronavirus 2019-nCoV vaccine development news published by Precision Vaccinations.